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Abstract: 
Immune checkpoint inhibitors, including those targeting programmed cell death protein 1 
(PD-1), are reshaping cancer therapeutic strategies. Evidence suggests, however, that tumor 
response and patient survival are determined by tumor programmed death-ligand 1 (PD-L1) 
expression. We hypothesized that preconditioning of the tumor immune microenvironment 
using targeted, virus-mediated interferon (IFN) stimulation, would upregulate tumor PD-L1 
protein expression and increase cytotoxic T cell infiltration, improving the efficacy of 
subsequent checkpoint blockade. Oncolytic viruses (OVs) represent a promising form of 
cancer immunotherapy. For brain tumors, almost all studies to date have used direct 
intralesional injection of OV, because of the largely untested belief that intravenous (i.v.) 
administration will not deliver virus to this site.  Here we show, in a window-of-opportunity 
clinical study, that i.v. infusion of oncolytic human Orthoreovirus (referred to herein as 
reovirus), leads to infection of tumor cells subsequently resected as part of standard clinical 
care, both in high-grade glioma (HGG) and in brain metastases, and increases cytotoxic T cell 
tumor infiltration relative to patients not treated with virus.  We further show that reovirus 
upregulates IFN-regulated gene expression, as well as the PD-1/PD-L1 axis in tumors, via an 
IFN-mediated mechanism. Finally, we show that addition of PD-1 blockade to reovirus 
enhances systemic therapy in a preclinical glioma model.  These results support the 
development of combined systemic immunovirotherapy strategies for the treatment of 
both primary and secondary tumors in the brain. 
 
 
 
  
 
Introduction: 
Therapies targeting T cell inhibitory checkpoint signalling pathways, including PD-1 
monoclonal antibodies, have produced unprecedented results in recent years in solid 
malignancies (1–4). Unfortunately, only a minority of patients benefit, with mounting 
evidence that tumor response and patient survival are associated with tumor PD-L1 
expression (5) and pre-existing tumor-infiltrating cytotoxic T cells (CD8+) (6). OV 
immunotherapy uses wild-type or genetically-modified viruses selectively to kill tumor cells 
and promote tumor-directed innate and adaptive immune responses (7, 8). The first OV to 
receive US Food and Drug Administration (FDA) approval was talimogene laherparepvec (T-
VEC), after a phase III trial demonstrating superior outcomes in patients with advanced 
melanoma treated with intratumoral T-VEC compared to subcutaneous granulocyte-
macrophage colony-stimulating factor (GM-CSF) (9). Major challenges remain, including the 
optimization of combination therapies and routes of virus delivery. In particular, the 
combination of OV with immune checkpoint blockade deserves attention, because a 
number of OVs stimulate the secretion of IFNs (10, 11), intermediary cytokines in PD-1/PD-
L1 expression. Furthermore, OV delivery to tumor can enhance T cell infiltration (11), hence 
priming the tumor immune microenvironment for immune-mediated therapy when 
combined with PD-1/PD-L1 axis blockade.  
For patients with brain tumors, concerns that the blood-brain barrier (BBB) may inhibit OV 
delivery have, thus far, limited studies using i.v. administration, notwithstanding the 
infiltrative and/or multifocal nature of such tumors. A number of OVs, including HSV-1716 
(12–14), HSV-G207 (15), adenovirus-dl1520 (ONYX-015)(16), and reovirus (17, 18), have 
been trialled in glioma patients by surgical intratumoral or intracavity injection. These 
  
 
techniques require careful patient selection and technically challenging neurosurgery, 
limiting repeat administration. Yet, the need for effective therapies in this group of patients 
cannot be overemphasized; median survival for grade IV gliomas (glioblastoma multiforme - 
GBM) after tumor-directed surgery and chemoradiotherapy is 14.6 months (19), and those 
with a single brain metastasis and controlled extracranial disease survive only nine to 10 
months, despite optimal treatment (20). The clinical trial described herein tested whether 
i.v. reovirus could infect recurrent HGGs and metastatic brain tumors in patients and 
examined the ensuing immunological sequelae, with particular focus upon the tumor 
microenvironment.  
Results: 
i.v. injected reovirus accesses brain tumors in mice 
Preclinical experiments confirmed that i.v. reovirus selectively accesses intracranially 
implanted malignant melanoma in immunocompetent mice, albeit to varying degrees (fig. 
S1). Reovirus σ3 capsid protein and reovirus RNA were strongly detected after i.v. infusion in 
mice 1 and 2, suggesting viral genome replication and translation, but were only detectable 
in extremely low amounts in mouse 3. Lower magnification pictures revealed high reovirus 
protein expression clustered in small areas of tumor, with lower expression in a larger 
number of tumor cells (fig. S1, middle row). Reovirus was not detected in normal peri-tumor 
murine brain tissue or PBS control. 
i.v. reovirus associates with multiple peripheral white blood cell subsets in patients 
On the basis of the murine experiment results, we recruited nine patients to a phase Ib 
window of opportunity trial (table S1), where each patient was treated with a single, one 
hour i.v. infusion of 1x1010 TCID50 (50 % tissue culture infectious dose) reovirus ahead of 
  
 
planned surgical resection of his or her brain tumor. Treatment was well tolerated in all 
cases, and surgery was undertaken three to 17 days after reovirus infusion. The most 
commonly observed adverse events were lymphopenia (grade 1-2 in all nine patients, grade 
3-4 in six patients) and flu-like symptoms. Median overall survival from the day of reovirus 
infusion to death was 469 days (range 118 to 1079 days), which is consistent with the 
expected survival for this group of patients that have variable cancer diagnoses. 
Extending upon findings from our previous study (21), where we demonstrated i.v. reovirus 
carriage and protection from neutralizing antibody by peripheral blood mononuclear cells 
(PBMCs), granulocytes, and platelets, we examined white blood cell subsets taken mid-
reovirus-infusion for reovirus RNA by RT-PCR (fig. S2A). In addition to granulocytes, we 
confirmed the association of reovirus RNA with CD14+ (monocytes, which are pivotal for 
reovirus cell carriage in mice (22)), CD19+ (B cells), and CD56+ (NK/NKT cells) fractions, but 
viral RNA could not be detected on CD3+ (T cells) in this subset of trial patients, for whom 
samples were available. Time-course analysis of IFN-α concentrations in patient sera taken 
before and after reovirus, revealed significantly increased IFN-α (P=0.0153) two days after 
infusion, in comparison to baseline (fig. S2B). This indicates reovirus engagement of 
pathogen recognition receptors, potentially during carriage by peripheral white blood cells, 
resulting in systemic IFN release. Plasma concentrations of other inflammatory cytokines 
were also increased two days after reovirus infusion, relative to pre-infusion concentrations 
(table S2). 
Reovirus is detected in resected brain tumors from trial patients  
Examination of resected brain tumors by immunohistochemistry (IHC) revealed the 
presence of reovirus σ3 capsid protein in low amounts in six out of nine tumours (Fig. 1A 
  
 
upper row and table S3) and nine out of nine tumors by immunogold transmission electron 
microscopy (TEM) (Fig. 1B). Resected brain tumor specimens from patients outside the trial 
served as controls. Secondary antibody-only controls for background immuno-gold staining 
in trial patient tumors are shown in fig. S3. The vast majority of reovirus protein was 
localized to tumor cells, with only 0-6 % localizing to endothelial cells (table S3 and fig. S4). 
Examination of the specimens by in-situ hybridization (ISH) revealed eight out of nine 
tumors to be positive for reovirus RNA (Fig. 1A lower row), with reovirus RNA being 
detected in a higher percentage of cells than reovirus σ3 protein in all cases (table S3), 
consistent with the findings in mice (fig. S1). In comparison, control brain tumors showed no 
reovirus RNA staining (Fig. 1A lower panel). The presence of reovirus RNA in tumors was 
further examined by qRT-PCR amplification of the S4 genome segment (encoding σ3), 
confirming four of the seven available tumor samples to be positive (Fig. 1C).  Despite some 
variation in detection limits for different techniques, together these data convincingly 
support delivery of systemically administered reovirus to patient brain tumors. 
The distribution of reovirus RNA and protein within tumors was further examined using 
immunofluorescence (IF) (Fig. 1D for trial tumors and fig. S5A for control). Reovirus RNA was 
detected in a large proportion of cells, whereas reovirus protein and protein-RNA co-
localization were only detected in discrete areas of tumor, suggesting that reovirus protein 
translation and/or productive infection occurred only in small areas of tumor, at least by the 
snapshot timepoint of surgical resection.  
The presence of reovirus RNA and protein in tumors correlates with Ki67 
The overall proportion of reovirus σ3 protein- and RNA-positive cells within individual 
tumors varied widely between the nine trial patients (table S3). Because actively dividing 
  
 
cells preferentially support reovirus replication in comparison to quiescent cells (23), (24), 
we analyzed resected trial patient and control tumors for expression of the proliferation 
marker Ki67 relative to reovirus protein/RNA (Fig. 2A, Fig. 2B, and table S4).  The amounts of 
both reovirus σ3 protein and RNA correlated with tumors containing a high proportion of 
Ki67-positive cells (P=0.014 for σ3 protein and P=0.016 for reovirus RNA). However, 
immunofluorescence analysis of tumors revealed little co-expression of reovirus RNA and 
Ki67 (Fig. 2C for trial tumors and fig. S5B for control), potentially because Ki67 staining is 
restricted to particular phases of the cell cycle (25). Further IF examination of tumors 
confirmed the presence of low amounts of reovirus σ3 protein, as was detected by IHC and 
TEM, and showed reovirus protein to frequently co-localize with tubulin, a key component 
of reovirus replication factories (Fig. 2D for trial tumors and fig. S5C for control) (26). 
Altogether, these results indicate that tumors with a higher proliferation index are more 
susceptible to reovirus infection, but that reovirus protein translation and/or productive 
infection overall occur at relatively low rates only. In keeping with these observations, and 
in contrast to our previous trial in resected colorectal liver metastases (21), replication-
competent reovirus could not be retrieved from any of the nine trial tumors. Analysis of the 
number of days between reovirus administration and surgery revealed no significant change 
in reovirus RNA and protein over time from reovirus infusion (fig. S6). 
Reovirus treatment increases tumor leukocyte infiltration 
We used RNAseq to compare expression of coding and non-coding transcripts in whole 
tumor RNA from three GBM trial patient samples (cases one, six, and seven), to that of three 
control GBM tumors. Given that sample numbers were small, criteria for statistically 
significant differential gene expression between treatment and control tumors were 
  
 
stringently set as described in the methods section (q<0.1). Of the 2366 sequenced 
transcripts, 102 genes were differentially expressed between reovirus-treated and 
untreated GBM groups (table S5). Two of these transcripts were CCL3 (mean control group 
expression = 4.2, mean treatment group expression = 34.3, q=0.0188) and CCL4 (mean 
control group expression = 2.5, mean treatment group expression = 19.2, q=0.0188), which 
both function to recruit CD8+ T cells and other leukocytes to sites of immunization (27). 
CCL4 protein and a number of other chemokines were higher in trial patient plasma two 
days after reovirus infusion, relative to pre-infusion concentrations (table S2).  Furthermore, 
peripheral blood assessment of CD4+ and CD8+ T cell populations revealed increased cell 
surface expression of intercellular adhesion molecule (ICAM) two days after i.v. reovirus 
infusion, in comparison to baseline expression (Fig. 3A). ICAM expression is upregulated by 
inflammatory cytokines, enhancing leukocyte interaction with vascular endothelial cells to 
enable migration to sites of inflammation (28). In keeping with these observations, IHC 
analysis of trial patient and control tumors revealed CD3+ T cells in and around blood vessel 
walls, in virus-treated but not untreated controls, consistent with reovirus-induced 
chemotaxis of T cells into infected brain tumors (Fig. 3B). Further IHC assessment for tumor-
infiltrating cytotoxic T cells (CD8+), which are critical for PD-1/PD-L1 directed 
immunotherapy (29), revealed their presence in eight of the nine trial patient tumors, four 
of which showed more staining (2+ or 3+), in comparison to the control cases, where  CD8+ 
T cell infiltration was detected only in three of the six tumors, all in low amounts (Fig. 3C and 
table S4). 
We also examined tumours for the presence of CD68+ microglia/infiltrating macrophages, 
and found these to be present in higher numbers in tumors from reovirus-treated patients 
  
 
in comparison to controls (fig. S7 and table S4). Very few tumor-infiltrating CD56+ natural 
killer cells and CD19+ B cells were found in any tumor. The daily dose of dexamethasone 
taken by patients within and outside the trial did not appear to correlate with tumour 
immune cell infiltration in the examined surgical specimens (table S4).  
Genes associated with programmed cell death are more highly expressed in GBM tumors 
from reovirus-treated patients than in matched controls 
Functional analysis of the differentially expressed genes found by RNAseq indicated 
significant enrichment in members of several biological processes, including those governing 
programmed cell death (P=0.0003), regulation of viral transcription (P=0.0000502), and 
cytokine activity (P=0.0129)(table S6). Consistent with these RNA expression data and 
preclinical models (30), IHC analysis of trial HGG samples revealed a higher proportion of 
tumor cells to be positive for cleaved caspase 3, albeit in a small number of patients, than in 
controls, suggesting the specific induction of apoptosis within tumors after i.v. reovirus 
infusion (Fig. 4A and table S4). A similar pattern was observed for the three trial brain 
metastases in comparison to controls (fig. S8A, table S4).  
PD-L1 expression is higher in tumors resected from reovirus-treated patients than in 
controls 
We next sought to determine whether reovirus treatment results in the upregulation of IFN-
regulated genes (IRGs). Of the 23,366 genes expressed in our samples, 5031 are IRGs (31), in 
contrast to 48 of the 102 genes that were differentially expressed between trial and control 
samples (chi-squared test, p=1.28x10-8).  
Interferon transcripts and PD-1 mRNA were not detected in our analysis, perhaps due to a 
transient rise and fall in expression before the timepoint of surgical resection. The 
  
 
expression of PD-L1 was, on average, about twice as high in reovirus-treated patient GBM 
samples than controls, but the difference was not statistically significant (1.310 in trial 
samples vs. 0.668 in controls). However, protein analysis by IHC revealed consistent PD-L1 
expression in trial HGGs, but not in controls (Fig. 4B and table S4), and a similar pattern was 
observed for brain metastases (fig. S8B, table S4). Of the two melanoma metastases in the 
trial, case nine, which stained most intensely for Ki67 and reovirus RNA, also displayed the 
strongest PD-L1 expression. Case five, in contrast, displayed relatively low expression of 
Ki67, reovirus RNA, and PD-L1 (fig. S8C). We sought to confirm these clinical findings in vitro; 
direct reovirus treatment of the established glioma cell line U87, primary human GBM cells 
(GBM1  and GBM4 (32)), and cell lines derived from metastatic breast cancer, colon cancer, 
and melanoma (MCF-7, SW620, and Mel624) significantly increased PD-L1 expression in U87 
(P=0.0021), GBM4 (P=0.0275), MCF-7 (P=0.0002), and SW620 cells (P=0.0062), with no 
significant differences in GBM1 and Mel624 cells (fig. S9A).  
We reasoned that reovirus treatment would also promote checkpoint protein expression 
within tumor-infiltrating immune cell populations. In vitro reovirus treatment of patient-
derived mixed HGG cell cultures from control patients outside the trial induced PD-L1 
upregulation within tumor-infiltrating lymphocytes (TILs), including helper/cytotoxic T cells, 
B cells, and NK cells (Fig. 4C, lower panel). This was also observed within PBMCs derived 
from the same patients (Fig. 4C upper panel), and in healthy donor PBMCs (fig. S9B). With 
regards to PD-1, higher protein expression was seen in both reovirus-treated HGGs and 
metastatic tumors in comparison to controls (Fig. 4D and table S4), as well as in healthy 
donor PBMC subsets after in vitro reovirus treatment (fig. S9C). 
 
  
 
Reovirus induces PD-L1 expression via an IFN-based mechanism 
We used GBM1 cells as an in vitro model of HGG tumor cells, to confirm an IFN-dependent 
mechanism for reovirus-induced stimulation of PD-L1 expression. GBM1 cells were treated 
using type I IFNs (IFN-α, IFN-β) and type II IFN (IFN-γ) in isolation or in combination. 
Whereas type I or type II IFN treatments each induced 50-70 % upregulation of PD-L1, the 
combination of type I and type II IFNs induced a 250 % increase in cell surface PD-L1 
expression. In contrast, combining IFN-α and -β, which bind the same type I IFN receptor, 
induced no further increase in PD-L1 expression over IFN-α alone (Fig. 4E and fig. S10A). 
Reovirus treatment of fresh patient-derived HGG single-cell suspensions (including all cell 
types contributing to the tumor immune microenvironment) generated reovirus-
conditioned medium (RCM), which contained high concentrations of type I and II IFNs (fig. 
S10B). RCM was filtered to remove reovirus, and conditioned medium (CM) controls were 
also filtered, to maintain experimental consistency. Soluble factors within HGG-RCM 
significantly upregulated GBM1 PD-L1 expression in comparison to CM (P=0.0481) (Fig. 4F 
and fig. S10C). To establish the relative contributions of type I and type II reovirus-induced 
interferons in the upregulation of PD-L1, we used PBMC-RCM (containing IFN-α, -β, and –γ) 
to treat GBM1 cells with concurrent blockade of interferon receptors and soluble 
interferons. Blockade of type I or II IFNs partially reduced PBMC-RCM-induced PD-L1 
expression on GBM1 cells, whereas blockade of both type I and II IFNs greatly diminished 
PD-L1 expression, confirming that type I and II IFNs co-operate to induce PD-L1 in patient-
derived glioma cells (Fig. 4G and fig. S10D).  
 
  
 
Sequential treatment using i.v. reovirus followed by PD-1/PD-L1 axis blockade improves 
survival in mice with brain tumors 
Based on the above data showing immune cell infiltration and upregulation of the PD-1/PD-
L1 axis by systemic reovirus in brain tumor patients, we sought to test survival using 
sequential OV-checkpoint inhibitor blockade in an immunocompetent orthotopic animal 
model of glioma.  Consistent with our trial data, C57/BL6 mice implanted intracranially with 
GL261 glioma cells exhibited improved survival using i.v. GM-CSF/reovirus (our optimal 
systemic reovirus regime (22)) over a two-week period, followed by a one-week period of 
PD-1 antibody treatment, compared to treatment with either virotherapy or checkpoint 
blockade alone (Fig. 5A). Comparison of hematoxylin and eosin-stained sections from brain 
tumors taken post-mortem from GM-CSF/reovirus-treated mice revealed prominent 
perivascular and intratumoral inflammatory infiltrate, containing lymphocytes (Fig. 5B). 
Further flow cytometry analysis of brain tumor single-cell suspensions revealed significantly 
higher active (IFN-γ+) helper (CD3+CD4+) and cytotoxic (CD3+CD8+) T cells within GM-
CSF/reovirus-treated tumors in comparison to PBS-treated tumors (P=0.0089 and P=0.0125, 
respectively, for helper and cytotoxic T cells, Fig. 5C).   
Discussion: 
Our data provide evidence of an OV, reovirus, gaining access to brain tumors after i.v. 
administration to patients. Reovirus RNA was widely detected in tumor cells of differing 
histological types. The i.v. route, therefore, holds promise as an efficient means of delivering 
OV to brain tumors, enabling regular scheduled treatments to be administered, while 
avoiding the need for neurosurgical methods of access.  
  
 
The tight window of opportunity between clinical presentation and planned brain surgery 
limited the number of patients able to participate in this study. Nonetheless, tumors from 
all nine treated patients, across a range of histological tumor types, showed evidence of 
reovirus infection. An ongoing clinical trial is assessing the safety and efficacy of i.v. reovirus 
in combination with post-operative chemoradiotherapy for patients with GBM (ReoGlio, 
ISRCTN70044565). Other OVs, including parvovirus H-1, are also being tested by i.v. infusion 
in patients with brain tumors (33).  
Previous studies have shown that apoptosis in malignant cells is induced after reovirus 
receptor binding and disassembly to form intermediate sub-virus particles, but that viral 
genome transcription and translation are not required (34). Hence, the lack of evidence for 
major reovirus productive infection in our study does not necessarily mean the absence of 
direct viral cytotoxicity. Indeed our RNAseq analysis and IHC for cleaved caspase 3 do 
indicate the induction of apoptosis.  Moreover, from an immunotherapy perspective, 
intracellular reovirus RNA is sufficient to engage pathogen recognition receptors, inducing 
interferon expression. Interferons are critical mediators of immune-mediated anti-cancer 
effects, for example by activating NK, T cell, and dendritic cell populations and enhancing 
antigen presentation (35). Future studies should, therefore, look to optimize reovirus 
treatment schedules to further increase the delivery of reovirus to tumor cells, given the 
absence of major reovirus productive infection.   
The BBB is known to be disrupted in brain tumors, as indicated by the presence of vasogenic 
edema (36). Nonetheless, many systemic anti-cancer agents, including monoclonal 
antibodies, are thought to be excluded by the BBB due to their higher molecular mass (37, 
38). The mechanism(s) by which reovirus enters brain tumors in comparison to tumors 
  
 
outside of the brain and its relation to the integrity of the BBB remain unclear, although the 
association of reovirus with multiple peripheral white blood cell subsets supports the idea 
that these immune cells may play a role in the delivery of virus to tumor. This is additionally 
supported by our observations of enhanced immune cell tumor infiltration after reovirus, 
and also by the clinically observed lymphopenia in all nine treated patients, a phenomenon 
that could be attributed at least in part to the accumulation of lymphocytes at the site of 
infection in tumor, consistent with previous reports of lymphopenia in acute viral infections 
(39). We found upregulation of CCL3 and CCL4 mRNA in brain tumors from reovirus-treated 
patients. These chemokines are upregulated in other acute viral encephalitis infections, 
including Semliki Forest Virus and West Nile Virus (40), whereas blockade of CCR5, whose 
ligands include CCL3 and CCL4 (41), decreases leukocyte migration into murine brains after 
viral infection (40). Pre-existing CD3+ and CD8+ TILs have a positive effect on survival in solid 
tumors, and  infiltrating cytotoxic T cells are critical for PD-1/PD-L1 directed immunotherapy 
(29, 42). In our trial, a proportion of brain tumors contained high numbers of cytotoxic T 
cells after reovirus treatment, a finding consistent with our murine data showing increased T 
cell infiltration into tumors after systemic reovirus treatment. Our data indicate lower 
baseline CD68 staining than in previous reports (43), potentially due to differences in 
staining methods. The functional relevance of increased CD68 cells in brain tumors after i.v. 
reovirus infusion and their origin remain unclear, warranting further investigation.  
Tumors from reovirus-treated patients exhibited more intense staining for both PD-1 and 
PD-L1, immune checkpoint proteins that are induced by IFNs. We further found evidence for 
both peripheral and tumor induction of IFNs, key cytokines in reovirus-mediated activation 
of immune cell populations (44). It has previously been shown that effector T cells 
  
 
upregulate PD-1 during the acute phase of viral infections, whilst maintaining activity, and 
that this protective response does not correspond to adverse outcomes (45, 46). One of the 
determinants of efficacy in PD-1 checkpoint blockade is tumor expression of PD-L1 (47). In 
GBM, PD-L1 expression is relatively weak in the majority of tumors (48). We found PD-L1 to 
be strongly upregulated by type I IFNs in combination with IFN-γ, cytokines that were 
secreted after ex vivo reovirus treatment of HGG cells. Hence, reovirus therapy may be used 
to improve clinical outcomes in patients with brain tumors by activating white blood cells, 
enhancing T cell infiltration into tumors, and upregulating PD-L1 there, in preparation for 
subsequent anti-PD-1 therapy. In support of our findings, a recent article by Ribas et al. has 
reported findings from the phase Ib portion of the Masterkey-265 study in extracranial 
advanced melanoma, where patients were treated using intratumoral injections of T-VEC 
(HSV type I encoding GM-CSF), with concomitant anti-PD1 therapy beginning six weeks after 
the start of OV therapy (49). Patients who responded to treatment in this study had 
increased CD8+ T cells and elevated PD-L1 protein expression on several cell subsets in 
tumors after OV therapy.  
The combination of i.v. OV with anti-PD-1 therapy for the treatment of brain tumors is the 
focus of investigations in our laboratory. Rational drug combinations that include anti-PD-1 
therapy for the treatment of brain tumors are all the more pertinent in light of the failure of 
single-agent nivolumab to deliver a survival advantage in patients with GBM (NCT02017717) 
(50). The challenges of local delivery of OVs into brain tumors are substantial, and direct 
intratumoral injection is inevitably suboptimal for multifocal/infiltrative disease.  Systemic 
virus-based immunotherapy provides a pragmatic alternative and appears capable of 
  
 
altering the immune microenvironment within brain tumors, which, in turn, could 
potentially improve cancer therapy when combined with immune checkpoint blockade.   
Materials and Methods: 
Study design: Clinical trial number (EudraCT) 2011-005635-10. This was an open-label, non-
randomized, single center study, which recruited nine adult patients between July 2013 and 
November 2014 at The Leeds Teaching Hospitals NHS Trust (LTHT), Leeds, UK. Patients were 
planned for debulking neurosurgery either for recurrent HGG or for metastatic tumor to the 
brain, as part of routine clinical care. A single one hour i.v. infusion of 1x1010 TCID50 reovirus 
was administered to patients ahead of surgery. The primary endpoint of the study was the 
presence of reovirus in the resected tumor sample. Tumors were initially analyzed for the 
presence of reovirus in batches of three. The trial achieved its primary endpoint and was 
closed after the recruitment of six patients with recurrent HGG and three with metastatic 
tumors to the brain, because reovirus was detected in all nine tumors. Inclusion criteria 
included adequate hematological and organ function and an Eastern Cooperative Oncology 
Group (ECOG) performance status ≤1. All patients gave written informed consent according 
to good clinical practice guidelines. Protocol, patient information sheet, and consent forms 
were approved by the United Kingdom Medicines and Healthcare products Regulatory 
Authority (MHRA), regional ethics review committee, as well as institutional review board at 
St James’s University Hospital. The trial management committee met on a monthly basis to 
discuss study progress, including patient safety and adverse events. Clinical patient safety 
assessments were performed within one week of start of treatment, on the day of reovirus 
infusion (day one), day three, the day of surgery and one month after surgery. Imaging was 
performed as for standard clinical care only. Control brain tumors were obtained from 
  
 
patients undergoing routine planned surgery at LTHT. Written informed consent was 
obtained in accordance with local institutional ethics review and approval. After surgery, all 
brain tumors were transported in L-glutamine-containing RPMI-1640 medium (Sigma) 
supplemented with 10 % FCS (Biosera) and 1 % (v/v) antibiotic antimycotic solution (Sigma). 
Reovirus: Clinical-grade reovirus Dearing type 3 (Reolysin) was provided by Oncolytics 
Biotech Inc. 
Animal experiments: In vivo animal models were approved by the University of Leeds Local 
Ethics Review Committee or the Mayo Foundation Institutional Animal Care and Use 
Committee. For fig. S1, six- to 10-week old C57/BL6 mice (Jackson Laboratories) were 
injected intracranially with 1x105 B16 melanoma cells and eight days later treated with a 
single injection of 1x108 PFU i.v. reovirus or PBS. Mice were sacrificed three days after 
treatment. For Figure 5, eight mice in each group were used; six- to eight-week old C57/BL6 
reovirus-vaccinated mice (22)  were injected intracranially with GL261 cells on day one. On 
day five, mice were treated using daily i.v. injections of 300 ng GM-CSF (Peprotech) and i.v. 
reovirus at 5x107 PFU or PBS as a control for five days. Treatments were repeated for a 
further five consecutive days starting on day 12. On days 19, 21, and 23, mice were treated 
with anti-PD-1 antibody (clone RMP1-14; Bio X Cell) or IgG isotype control (clone MPC11; 
Bio X Cell) by i.p. injections. Mice were regularly monitored for any signs of deterioration or 
weight loss, upon which animals were sacrificed and the duration of survival recorded. 
IHC, ISH, and IF: These techniques were performed on formalin-fixed paraffin-embedded 
tissue sampled randomly from one to two areas of resected patient or animal tumor. Tissue 
for IHC was processed using an automated Bond Max system (Leica Biosystems) as 
described (51). Reovirus σ3 and cleaved caspase 3 antibodies were diluted 1:1000. IHC 
  
 
detection of PD-1, PD-L1, CD3, CD8, CD68, and Ki67 used an automated Bond Max system 
(Leica Biosystems) according to manufacturer’s protocol. Primary antibodies (all Abcam) 
were diluted either 1:500 (PD1 and PD-L1) or 1:200 (CD3, CD31, CD8, CD68, Ki67). The 
percentage of positive cells was determined using the InForm system (Perkin Elmer). ISH for 
reovirus RNA and IF for reovirus σ3 protein, reovirus RNA, and tubulin were performed as 
previously described (51), (21). IF nuclear counterstaining was with DAPI diluted 1:10,000 
(ThermoFisher Scientific). One to two slides per tumor were examined for quantification of 
reovirus σ3 protein and reovirus RNA, whereas two to three slides per tumor were 
examined for quantification of Ki67, PD-1, PD-L1, and CD markers. 
Peripheral reovirus carriage RT-PCR: Peripheral blood samples taken from study patients 
mid-reovirus-infusion were collected, fractionated for PBMCs and granulocytes, then RNA 
extracted as previously described (21). PBMC subsets were isolated by MACS Microbead 
selection (Miltenyi Biotec) according to manufacturer’s instructions. PCR conditions and 
primers were also previously described (52). Samples were run on 2 % agarose gels 
alongside a 100 bp DNA ladder (New England Biolabs). 
Tumor reovirus qRT-PCR: Tumor tissue was disaggregated using a Cell Dissociation Sieve & 
Tissue Grinder Kit (Sigma). 1 µg of Trizol (Sigma) -extracted RNA was reverse-transcribed 
(Bioline SensiFast cDNA Synthesis kit) according to manufacturer’s instructions in 20 µl 
reactions. 2 µl of the resultant reaction containing cDNA was subjected to standard qPCR 
using SYBR Green PCR Master Mix (Life Technologies) and primers specific to the reovirus σ3 
gene, to amplify a 61 bp product (forward 5’ GATGCGCCAATGTCTAATCA 3’, reverse 5’ 
CTCCTCGCAATACAACTCGT 3’; both Sigma). QuantiTect primers (Qiagen) specific to 18S 
rRNA served as cellular RNA controls. 
  
 
RNAseq: Three control GBM tumors were compared to three GBM tumors from reovirus-
treated trial patients. RNA sequencing libraries were prepared using the Truseq Stranded 
Total RNA Library Prep Kit (Illumina), and 150 bp paired end reads were sequenced on a lane 
of the Illumina HiSeq3000. Reads were quality-processed and aligned as described 
previously (53). Expression analysis was performed using the Cufflinks suite of programs 
(54). Briefly, expression was quantified using cuffquant with multi-read correction and 
abundant non-informative transcripts (ribosomal and mitochondrial RNAs) masked. 
Differential expression analysis between the control (patients without reovirus) and treated 
(patients receiving reovirus) groups was then performed using cuffdiff with a false discovery 
rate (FDR) of 0.1. Gene set analysis of the resulting significantly differentially expressed 
genes was performed using hypergeometric testing via WebGestalt (55), with the set of 
genes expressed in any sample as the reference set. 
Processing of HGG single-cell suspensions and PBMCs: 
Written informed consent was obtained in accordance with local institutional ethics review 
and approval. HGG tumor samples were processed using a Brain Tumor Dissociation Kit 
(Miltenyi Biotec), according to the manufacturer’s instructions. Briefly, tumor tissue was 
homogenized and digested in gentleMACS C tubes using a dissociator and buffers and 
enzymes supplied by the manufacturer, then incubated at 37oC. Single-cell suspensions 
were passed through a 70 µm filter. Where appropriate, samples were demyelinated using 
Myelin Removal Beads II (Miltenyi Biotec). Paired PBMC samples were derived from the 
same patients by step density centrifugation over Lymphoprep (Axis-Shield). 
Culture of GBM1, GBM4, MCF-7, U87, SW620, and Mel624 cell lines: 
  
 
All cells were cultured at 37 °C with 5 % CO2. The human breast adenocarcinoma cell line, 
MCF-7, human colorectal cancer cell line, SW620, human glioblastoma cell line, U87, and 
the human melanoma cell line, Mel624, were maintained in L-glutamine-containing 
Dulbecco’s Modified Eagle’s Medium (DMEM; Sigma) supplemented with 10 % (v/v) fetal 
calf serum (FCS). GBM1 and GBM4 cells were adherently propagated on plasticware coated 
with poly-L-ornithine (Sigma; 5 μg/ml) and laminin (Invitrogen; 5 mg/ml) and cultured in 
Neurobasal medium supplemented with 0.5X B27, 0.5X N2 (all from Thermofisher), 
recombinant human basic fibroblast growth factor (bFGF; 40 ng/mL; Gibco), and epidermal 
growth factor (EGF; 40 ng/ml; R&D Systems). 
Generation of CM and RCM from fresh patient HGG samples and PBMCs: 
HGG single-cell suspensions or PBMCs were cultured for 24 hrs at 2x106/ml alone (CM), with 
50 PFU/cell reovirus (HGG-RCM), or with 1 PFU/cell reovirus (PBMC-RCM) in L-glutamine-
containing RPMI supplemented with 10 % (v/v) FCS. Cell-free supernatants were collected, 
and reovirus was removed by filtration through Millipore OptiScale 25 filters. CM and RCM 
were stored at -80 ⁰C until required.  
Flow cytometry: 
Flow cytometry was performed on an LSRII flow cytometer, and data were analysed using 
FACSDiva (both Beckton Dickinson) or FlowJo (Treestar). Relative fluorescence shift (RFS) 
was calculated using the formula 𝑅𝐹𝑆 =
(𝑀𝐹𝐼 𝑜𝑓 𝑡𝑟𝑒𝑎𝑡𝑚𝑒𝑛𝑡 𝑠𝑎𝑚𝑝𝑙𝑒−𝑖𝑠𝑜𝑡𝑦𝑝𝑒)
(𝑀𝐹𝐼 𝑜𝑓 𝑐𝑜𝑛𝑡𝑟𝑜𝑙 𝑠𝑎𝑚𝑝𝑙𝑒−𝑖𝑠𝑜𝑡𝑦𝑝𝑒)
   
where MFI is median fluorescence intensity. To create overlay plots in FlowJo, the y-axis was 
normalized to mode.  
  
 
Direct reovirus stimulation of patient HGG and PBMC: HGG single-cell suspensions and 
PBMCs were plated separately at a density of 2x106/ml and cultured with or without 
reovirus at 1 PFU/cell for 48 hrs in RPMI supplemented with 10 % FCS.  Samples were 
harvested and washed with isotonic buffer (PBS/0.05 % BSA) before staining with the 
following antibodies: CD45-FITC (H130), CD8-BV421 (RPA-T8), CD20-BUV395 (2H7), NKp46-
APC (9E2/Nkp46), and PD1-PE (MIH4) from BD Biosciences; CD3PerCP (BW264/56) and CD4-
PEvio770 (M-T466) from Miltenyi Biotec; CD69-BV421 FN50 and PDL1-PE (29E.2A3) from 
Biolegend; mouse CD3-FITC, CD4-Percp, and CD8-PE (eBioscience); mouse intracellular IFN-
γ-PE-Cy7 (Biolegend).  
Direct reovirus stimulation of primary human cells and cell lines: GBM1, GBM4, MCF-7, 
U87, SW620, and Mel624 cells were cultured overnight at 1x105 cells/well. Reovirus (0, 1, or 
10 PFU/cell) was then added for 24 hrs before cells were harvested and stained with anti-
human PD-L1-PE (clone MIH1; eBioscience) as above.   
Treatment of GBM1 using exogenous, purified IFNs: GBM1 cells were cultured overnight at 
1x105 cells/well. Cells were then treated with 100 pg of recombinant human IFN-α (R&D 
Systems), IFN-β (PBL Interferon Source), or IFN-γ (Peprotech) alone or in combination. After 
24 hrs, cells were harvested and stained with anti-PD-L1-PE as above. 
Treatment of GBM1 using HGG-derived CM / RCM: GBM1 cells were cultured as above, 
then treated with 500 µl of a 1:16 dilution of CM or RCM for 24 hr before being stained for 
PD-L1 expression as above. 
 
 
  
 
Treatment of GBM1 cells using PBMC-derived CM/RCM and IFN blockade:  
GBM1 cells were cultured at 5x104 cells/well. After 24 hrs, thawed CM and RCM were 
incubated for 1 hr at 4 ⁰C with 0.75 % anti-human-IFNα, -IFNβ, or -IFNγ blocking antibody 
(alone or in combination; all Pestka Biomedical Laboratories, PBL) or isotype control (rabbit 
serum (IFNγ) or sheep serum (IFNα and IFNβ) alone or in combination; both Sigma). 
Simultaneously, when GBM1 cells were to be treated with anti-human-IFNα/IFNβ blocking 
antibodies, 1.25 % anti-human IFNα/β receptor chain 2 antibody (PBL), or IgG2a isotype 
control (R&D Systems) were added to cells for 1 hr at 37 ⁰C.  Prepared CM/RCM (including 
block/isotype) was then added for 4 hrs at 37 ⁰C before medium was removed and replaced 
with full growth medium. After 24 hrs, cells were harvested and stained for PD-L1 
expression as described above. 
Determination of cytokine and chemokine concentrations: 
BioRad Bio-Plex Pro Cytokine and Chemokine Assays (21-plex, human group I and 27-plex, 
human group II) were used to determine concentrations of soluble mediators in plasma, as 
per manufacturer’s instructions.  
Cytokine secretion from fresh ex-vivo HGG single-cell suspensions: IFN-α (Mabtech) and IFN-
γ (BD Biosciences) were detected by ELISA using matched antibody pairs, whereas IFN-β was 
detected using a Verikine Human IFN Beta ELISA Kit (PBL) as previously described (30).  
Cytokine secretion from patient serum: IFN-α was detected using a Verikine Human IFN-α 
Multi Sub-type Serum ELISA Kit, as per manufacturer’s instructions.  
Transmission electron microscopy: This method was performed as previously described 
(21).  
 
  
 
Statistical analysis: 
All statistical analysis was conducted using GraphPad Prism software. Asterisks in Fig. 5C, fig. 
S2B, fig. S8, and fig. S9 represent P < 0.05 using a t-test. The statistical correlation of 
reovirus RNA / protein with Ki67 (Fig. 2B) and with time between infusion and surgery (fig. 
S6) was determined by linear regression.   
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Figure Legends: 
 
Fig. 1. Intravenous delivery of reovirus to primary and secondary brain tumors.  
  
 
A) Representative IHC and ISH trial and control patient tumor sections stained for 
reovirus σ3 protein (brown - top row) and reovirus RNA (blue - bottom row). The ‘control 
breast met’ is a metastasis to the brain from a breast cancer primary. Arrows point to 
examples of positive cells / positive areas of tissue. Scale bars = 20 μm. B) Trial and control 
patient tumor immunogold-TEM images for reovirus σ3 protein (arrows). Scale bar = 200 
nm. C) qRT-PCR for reovirus σ3 gene, using whole tumor RNA. Data indicate fg reovirus RNA 
per µg of whole tumor RNA. Histogram shows the mean of triplicate samples, and error bars 
indicate standard deviation. D) Representative IF of trial patient tumor sections showing 
staining for reovirus RNA (blue), reovirus σ3 protein (red), and their co-expression (yellow).  
Scale bars = 80 μm.   
 
Fig. 2. Correlation of reovirus RNA / protein with proliferating tumor cells 
  
 
A) Trial patient IHC tumor sections stained for Ki67 (brown) with indicated percentages of 
cells positive for Ki67 and reovirus σ3 protein (from table S3), showing examples of tumors 
with high reovirus σ3 staining (top row) and no reovirus σ3 protein staining (bottom row). 
Scale bars = 40 μm. B) Scatter plot and line of best fit, correlating the percentages of tumor 
cells positive by IHC for reovirus RNA or σ3 protein and for Ki67. C) Representative tumor 
sections derived from trial patient nine (high Ki67, top row), trial patient one (intermediate 
Ki67, middle row), and trial patient four (low Ki67, bottom row), showing IF staining for 
reovirus RNA (blue), Ki67 (red), or their co-expression (yellow, arrows). Scale bars = 40 μm. 
D) Representative trial patient tumor IF staining for tubulin (fluorescent red), reovirus σ3 
protein (fluorescent green) and their co-expression (yellow). Nuclear counterstaining is blue. 
Top and bottom row scale bars = 40 μm. Middle row scale bar = 80 μm.
 
Fig. 3. Tumor immune cell infiltration 
  
 
A) Fold change in cell-surface ICAM expression on CD4 and CD8 T cells from trial patients’ 
peripheral blood. B) Trial and control patient IHC tumor sections stained for CD3 (brown). 
Scale bars = 20 μm. ‘V’ indicates blood vessel. C) Trial and control patient IHC tumor sections 
stained for CD8 (brown). Scale bars = 20 μm. 
 
 
Fig. 4. Expression of cleaved caspase 3, PD-L1, and PD-1 in high grade gliomas after 
reovirus treatment  
  
 
A) Representative trial and control patient HGG sections stained for cleaved caspase 3 
(brown) by IHC. Scale bars = 60 μm. B) Representative trial and control patient HGG sections 
stained by IHC for PD-L1 (brown). Scale bars = 30 μm. C) Representative (one of three 
samples tested) flow cytometry for PD-L1 on GBM TILs (bottom row) or PBMCs (top row) 
derived from the same patient, after stimulation for 48 hours using 1 PFU/cell reovirus. D) 
Representative trial and control patient HGG sections stained by IHC for PD-1 (brown). Scale 
bars = 30 μm. E) Representative flow cytometry for PD-L1 on GBM1 cells after stimulation 
with combinations of purified IFN-α/-β/-γ for 24 hr, each at 100 pg/ml. F) Representative 
flow cytometry for PD-L1 on GBM1 cells after stimulation with ex vivo HGG-derived CM or 
RCM for 24 hours (at a concentration of 1:4 of conditioned medium to native medium). G) 
Representative flow cytometry for PD-L1 on GBM1 cells after stimulation using PBMC-
derived CM or RCM for 24 hours (at a concentration of 1:4 of conditioned medium to native 
medium) with blockade of IFN-α+β/γ/ α+β+γ or equivalent isotype controls. 
 
Fig. 5. Combination i.v. reovirus and checkpoint inhibition in an orthotopic syngeneic brain 
tumor model 
  
 
C57/BL6 reovirus-vaccinated mice (22) were injected with GL261 cells intracranially on day 
one and treated using combinations of GM-CSF plus i.v. reovirus and/or anti-PD-1 antibody. 
A) Kaplan-Meier survival plot, with Mantel-Cox comparison of survival curves: control vs. 
Anti-PD-1 P=0.4617, control vs. GM-CSF/reovirus P=0.0012, control vs. GM-CSF/reovirus + 
anti-PD-1 P<0.0001, GM-CSF/reovirus vs. GM-CSF/reovirus + anti-PD-1 P<0.0001, anti-PD-1 
vs. GM-CSF/reovirus + anti-PD-1 P<0.0001. B) Representative brain tumor hematoxylin and 
eosin stained sections from PBS- and GM-CSF/reovirus treated mice. Black arrows mark 
vascular endothelial cells; white arrows mark lymphocytes. Scale bars = 30 μm. C) Flow 
cytometry quantification of CD3+ CD4+ IFN-γ+ or CD3+ CD8+ IFN-γ+ tumor-infiltrating 
lymphocytes from PBS or GM-CSF/reovirus-treated mice. Graph shows the mean ± SD of 
four samples.   
 
 
